RDY

DR REDDYS LABORATORIES LTD RDY

NYSELarge CapHealthcare
InternationalScored off the official board: an annual-only filer, so this data lags a domestic quarterly filer.

13F Pro quality score

Rank #1,419 of 2,925TOP 50%

Why it scores 53Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$3.58B

Quarter to Mar 31

Net income

$456.00M

Quarter to Mar 31

Free cash flow

$358.00M

Quarter to Mar 31

Operating margin

15.1%

Quarter to Mar 31

Top Institutional Holders

as of Q2 2026
$1.82B total
Robeco Institutional Asset Management B.V.
$261.13M+4.9%
MORGAN STANLEY
$158.47M+16.7%
BlackRock, Inc.
$153.39M-8.6%
ROYAL BANK OF CANADA
$133.51M-7.7%
Aikya Investment Management Ltd
$123.08M+6.2%
RENAISSANCE TECHNOLOGIES LLC
$106.46M-6.5%
DIMENSIONAL FUND ADVISORS LP
$77.04M-0.2%
JPMORGAN CHASE & CO
$60.47M-6.9%
STATE STREET CORP
$59.77M+2.4%
ALLIANCEBERNSTEIN L.P.
$51.67M+46.8%
VANGUARD CAPITAL MANAGEMENT LLC
$44.93M0.0%
FRANKLIN RESOURCES INC
$41.22M-0.4%
Nuveen, LLC
$40.97MNew
BNP PARIBAS FINANCIAL MARKETS
$38.40M-16.8%
ACADIAN ASSET MANAGEMENT LLC
$32.74M-6.2%
MARSHALL WACE, LLP
$29.35M-24.0%
BESSEMER GROUP INC
$26.91M+1.9%
AMERICAN CENTURY COMPANIES INC
$26.53M+10.2%
SCHRODER INVESTMENT MANAGEMENT GROUP
$24.05M+793.0%
UBS Group AG
$24.03M+6.8%
VANGUARD PORTFOLIO MANAGEMENT LLC
$22.06M-14.2%
Creative Planning
$17.98M+6.3%
LAZARD ASSET MANAGEMENT LLC
$17.85M+16.2%
GOLDMAN SACHS GROUP INC
$15.27M+74.8%
NORTHERN TRUST CORP
$14.99M-5.0%
See all 240 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

FY 2026
EDGAR

Net Income

FY 2026
EDGAR

EPS (Diluted)

FY 2026
EDGAR

Operating Margin

FY 2026
EDGAR

ROIC

FY 2026
EDGAR

Free Cash Flow

FY 2026
EDGAR

Loading ratio trend…

RDY key financials by period

Reported revenue, net income and operating margin by fiscal year, from DR REDDYS LABORATORIES LTD's annual filings on SEC EDGAR.

DR REDDYS LABORATORIES LTD reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2026$3.6B$456.0M15.1%
FY 2025$3.8B$663.0M22.1%
FY 2024$3.4B$668.0M24.3%
FY 2023$3.0B$548.0M23.2%
FY 2022$2.8B$311.0M13.8%
FY 2021$2.6B$236.0M12.8%
Source: RDY filings on SEC EDGAR →

Companies similar to RDY

Ranked by quality-factor profile and overlapping institutional ownership, from the latest 13F filings and SEC financials.

About DR REDDYS LABORATORIES LTD (RDY): stock profile, AI score and financials

DR REDDYS LABORATORIES LTD (RDY) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores RDY at 53.1/100 on a composite quality score built from its SEC filings, placing it at rank #1,419 of 2,925 stocks — the top half of the AI-ranked universe. Based on the latest XBRL financial filings (FY 2026), DR REDDYS LABORATORIES LTD reports quarterly revenue of $3.6B, net income of $456.0M, an operating margin of 15.1%. Top institutional holders of RDY by reported 13-F value include Robeco Institutional Asset Management B.V., MORGAN STANLEY, BlackRock, based on the most recent SEC filings. RDY trades on the NYSE exchange and files with the SEC under CIK 1135951. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate RDY daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for DR REDDYS LABORATORIES LTD directly from SEC EDGAR.

SEC EDGAR: CIK 1135951 →